EDIT vs LLY · rev $32.3M vs P/E 39, rev $65.18B
Editas Medicine Inc (EDIT) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported LLY revenue for 2025-12-31 was $65.18B. Net income was $20.64B. Revenue was up 44.7% from 2024-12-31 to 2025-12-31. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
EDIT currently screens at market cap $375.2M. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the EDIT and LLY stock pages for the full models.
Not investment advice.